Technology Networks spoke to the co-founder of Field Trip Health, a Toronto-based provider of ketamine therapy, on why 2021 was such a significant year for psychedelics.
To discuss the chromatographic challenges posed by novel cannabinoids, Analytical Cannabis recently spoke with Sean Orlowicz, business development manager for food and cannabis at Phenomenex.
To date, no classical psychedelic agents have been approved for use as a medicine but what does convention tell us about the way these drugs will be scrutinized and assessed for quality?
Stephen Wright reviews the status of pre-clinical and clinical research into the use of LSD to treat a range of conditions and provide insights into the future of research involving this drug.
If environmental factors don't lead to hot hemp, which varieties of hemp should farmers opt for? Analytical Cannabis spoke with Jacob Toth, a graduate student at Cornell University’s College of Agriculture, to find out.
In this article, Technology Networks considers how qPCR works, experimental requirements, data analysis and applications of the technique.
Illegal cannabis grows are often hidden within US national forests, where they wreak damage on the local wildlife.
The year posed many challenges, but cannabis businesses, research centers, and reform groups still managed to make impressive headway. Analytical Cannabis looks back on the stories and issues that dominated the cannabis industry in 2021.
Kimberly Ross of Peak Compliance Labs outlines the many obstacles hemp faces before it becomes fully regulated in the US.